New Heart Imaging System Awaits U.S. Clearance

Patients undergoing catheter-based heart procedures may gain a new imaging option once the U.S. approves it.

Updated on Nov. 2, 2026 in Heart Disease

New Heart Imaging System Awaits U.S. Clearance

GE HealthCare unveiled Allia Celeo, a ceiling-mounted image-guided system for cardiology and interventional radiology, at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego on November 1. The system is CE marked and pending clearance with the U.S. Food and Drug Administration, so it is not yet available for sale in the United States.

Why it matters

Image-guided systems shape how clinicians visualize blood vessels and the heart during catheter-based procedures, which affects how precisely those procedures can be planned and performed. Because Allia Celeo is still awaiting U.S. clearance, its practical effect on American patients is not yet established and will depend on regulatory review and adoption by hospitals.

The announcement is a manufacturer product unveiling rather than a clinical study, so no trial, sample size, or patient outcome results were reported. Performance claims available so far describe the system's design features rather than measured clinical benefit.

The players

GE HealthCare

A medical technology company whose imaging portfolio includes cardiology and interventional radiology systems used in catheter-based procedures.

U.S. Food and Drug Administration

The federal agency that reviews and clears medical devices, including image-guided systems, before they can be sold in the United States.

The details

Allia Celeo uses an extra-wide-bore C-arm mounted on a ceiling gantry with integrated cabling, designed to reach steep angles, including in patients with a high body mass index. An on-screen digital twin assists with positioning of the gantry and table, and an AI-enabled image chain automatically adjusts acquisition settings to balance image quality against radiation dose across 2D and 3D imaging. The system also offers InnovaBreeze, which uses automated table and gantry movement to image the full lower limbs in a single acquisition, and it works with StentViz, Valve Assist 2, Embo Assist AI, and the Mac-Lab hemodynamic system, as well as compatible third-party intravascular imaging and physiology systems.

- The system was unveiled on November 1, 2026, at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego.
- The U.S. Food and Drug Administration clearance is still pending as of the unveiling.

Health Landscape

Catheter-based cardiac and vascular procedures increasingly rely on real-time imaging systems that guide device placement and reduce reliance on manual positioning. Allia Celeo continues GE HealthCare's recent push to expand its Allia line of image-guided systems for these procedures.

If you have a heart condition that may need a catheter-based procedure, it is reasonable to ask your cardiologist which imaging tools your care team uses. This system is not yet available in the United States, so it will not affect your care until it is cleared and adopted by a hospital.

The takeaway

Image guidance is one of several tools that help clinicians plan heart procedures more precisely. Ask your cardiologist which imaging technologies are used in your care, and keep in mind that newly unveiled devices typically need regulatory clearance before they reach patients.